Recombinant adeno-associated virus expressing human papillomavirus type 16 E7 peptide DNA fused with heat shock protein DNA as a potential vaccine for cervical cancer.
about
Antigen-specific immunotherapy of cervical and ovarian cancerPerspectives for therapeutic HPV vaccine developmentInduction of CD8 T cells by vaccination with recombinant adenovirus expressing human papillomavirus type 16 E5 gene reduces tumor growthImmunotherapy for cervical cancer: Research status and clinical potentialIntranasal vaccination with recombinant adeno-associated virus type 5 against human papillomavirus type 16 L1Optimisation of DNA vaccines for the prophylaxis and modulation of herpes simplex virus infections.Immune responses to adeno-associated virus and its recombinant vectors.Therapeutic vaccination for the treatment of mucosotropic human papillomavirus-associated disease.A nonproliferating parvovirus vaccine vector elicits sustained, protective humoral immunity following a single intravenous or intranasal inoculationDevelopment of HPV vaccines for HPV-associated head and neck squamous cell carcinoma.Preventative and therapeutic vaccines for cervical cancer.DNA vaccines expressing antigens with a stress protein-capturing domain display enhanced immunogenicity.Intranasal immunization with synthetic peptides corresponding to the E6 and E7 oncoproteins of human papillomavirus type 16 induces systemic and mucosal cellular immune responses and tumor protectionAdeno-associated virus vectors: potential applications for cancer gene therapy.New dimensions in vaccinology: A new insight.Human papillomavirus type 16 E5 protein as a therapeutic target.Complement is an essential component of the immune response to adeno-associated virus vectors.Preventive and Therapeutic Vaccines against Human Papillomaviruses Associated Cervical CancersRole of human papillomavirus and cell cycle-related variants in squamous cell carcinoma of the oropharynx.Human papillomavirus vaccines for the treatment of cervical cancer.Human papillomavirus therapeutic vaccines in head and neck tumors.Regulatory function of in vivo anergized CD4(+) T cellsThe TLR9-MyD88 pathway is critical for adaptive immune responses to adeno-associated virus gene therapy vectors in mice.Immunization with adenoviral vectors carrying recombinant IL-12 and E7 enhanced the antitumor immunity against human papillomavirus 16-associated tumor.AAV Vectors Vaccines Against Infectious Diseases.Novel adeno-associated virus vector vaccine restricts replication of simian immunodeficiency virus in macaques.Characterization of HPV18 E6-specific T cell responses and establishment of HPV18 E6-expressing tumor model.Current state in the development of candidate therapeutic HPV vaccinesThe current state of therapeutic and T cell-based vaccines against human papillomaviruses.Successful interference with cellular immune responses to immunogenic proteins encoded by recombinant viral vectors.Antigen fusion with C3d3 augments or inhibits humoral immunity to AAV genetic vaccines in a transgene-dependent manner.Expression and purification of recombinant proteins based on human prostate stem cell antigen and heat shock protein-70.Secretory heat-shock protein as a dendritic cell-targeting molecule: a new strategy to enhance the potency of genetic vaccines.Immunization strategy against cervical cancer involving an alphavirus vector expressing high levels of a stable fusion protein of human papillomavirus 16 E6 and E7.Vaccines based on novel adeno-associated virus vectors elicit aberrant CD8+ T-cell responses in mice.Both antigen optimization and lysosomal targeting are required for enhanced anti-tumour protective immunity in a human papillomavirus E7-expressing animal tumour model.Intratumoral gene therapy of malignant brain tumor in a rat model with angiostatin delivered by adeno-associated viral (AAV) vector.Immunity to adeno-associated virus serotype 2 delivered transgenes imparted by genetic predisposition to autoimmunity.Factors influencing cross-presentation of non-self antigens expressed from recombinant adeno-associated virus vectors.Antigen-specific humoral tolerance or immune augmentation induced by intramuscular delivery of adeno-associated viruses encoding CTLA4-Ig-antigen fusion molecules.
P2860
Q27488697-242A68F9-84A2-47B3-BF5A-DAC93C945EE5Q28069272-0B2700C4-39E1-4BB7-86DD-D67D369FD4A6Q33604559-D6748148-9777-4E7E-8C4B-3F4A01B22EE5Q34033763-1599A01E-30C5-42A0-9E37-AA800A885259Q34434903-D2AE81D5-1941-46DD-AEB3-91AA03E18713Q34452049-C5A68735-FEB6-4746-AC83-8D8121FA02EEQ35131229-318B6582-5AA3-421C-BCFC-DA04BE63D947Q35144042-E96CC7ED-7F1D-4453-B8F3-7ACBBD405BE6Q35543174-6DA41813-455D-4610-AD61-77A1C775059FQ35552591-CBB97A88-E3CD-4CB9-9CC1-77538FCC75BCQ35623323-4F2982FF-D0BE-48CB-B922-6AE4996BFE23Q35826374-CF814A87-DDA7-4EA0-A391-62398B143A9AQ36095558-F176DD5A-CD01-46D8-B0FB-D82A70050F19Q36165834-6CCD8C02-6EF1-409A-ABC9-F6BB17DF15B6Q36265802-79331486-610D-44D3-A483-4ECC84449692Q36406751-995F4927-3702-4B26-B4BE-4D25954EAC78Q36484108-309DED3A-92C1-440E-90EB-71F2206B2680Q36652548-CF900B3A-0CA8-4357-BF17-8B2030529F4DQ36681902-75066C38-8E99-418E-A44F-063D5814615EQ36690278-21023787-86F6-45AE-AAD8-638CB577FAEAQ36817148-781300C5-567B-420D-8F89-B8FF9FD2B9A7Q37113443-9FCDFAB9-9F04-40E7-ABF4-1E034BBA630BQ37286686-B74A13F0-EF27-4C76-ABF7-A4FC22332897Q37447027-8D3EB4D6-D3AF-47A8-8F11-489A2E02EBBBQ37498000-FC6EB1EC-36CF-4D2A-A6ED-2EC77221F8BAQ37743813-CDED7A6E-133D-4F9B-B827-DCAAB20B9E59Q38700706-DB0AB294-D235-4EDB-BC15-833CA93B0772Q38743922-D740D936-BB3C-4F6F-88DA-5B477F1E5CD2Q39033576-9458B219-2D1D-44F5-88BE-539139882F22Q39601191-BA4ACB64-1BBE-42A3-BB14-426E00C8A609Q39771124-09100CBD-EA68-4157-B70D-3A36DEA4B641Q39872774-59EB7DB2-407D-4016-892C-919AA491E766Q40566671-8AD745E3-6EF4-4F8C-8D6A-8D1E18C4CD85Q40749345-D7395622-D6B0-41B5-89CE-D35698F3F67BQ42121728-6CF013D4-FDD0-4043-8AD8-0F2437F42052Q43854654-98001791-B3A1-4618-A1A6-1DEAA0625E15Q43890874-C4BE8B75-82B9-4DBB-A65C-89A6D21AF362Q45698037-9D4422B6-8821-438E-97EA-481DAF62ED22Q45736630-D113D197-2D85-4E27-A361-DC6EFC124BA2Q45881605-AAC213E8-B4C4-4EDF-8694-D05D21835B1E
P2860
Recombinant adeno-associated virus expressing human papillomavirus type 16 E7 peptide DNA fused with heat shock protein DNA as a potential vaccine for cervical cancer.
description
2000 nî lūn-bûn
@nan
2000 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի մարտին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Recombinant adeno-associated v ...... l vaccine for cervical cancer.
@ast
Recombinant adeno-associated v ...... l vaccine for cervical cancer.
@en
type
label
Recombinant adeno-associated v ...... l vaccine for cervical cancer.
@ast
Recombinant adeno-associated v ...... l vaccine for cervical cancer.
@en
prefLabel
Recombinant adeno-associated v ...... l vaccine for cervical cancer.
@ast
Recombinant adeno-associated v ...... l vaccine for cervical cancer.
@en
P2093
P2860
P1433
P1476
Recombinant adeno-associated v ...... l vaccine for cervical cancer.
@en
P2093
P2860
P304
P356
10.1128/JVI.74.6.2888-2894.2000
P577
2000-03-01T00:00:00Z